Clinical Indications for Simethicone and Activated Charcoal
Activated Charcoal
Activated charcoal is indicated for acute ingestion of selected toxic substances, administered at 1-2 g/kg (or 50-100 g for adolescents/adults) within 1 hour of ingestion when the airway is protected and the patient is fully conscious 1.
Primary Indication: Acute Poisoning/Overdose
Activated charcoal works by reducing absorption of ingested toxins from the gastrointestinal tract. The 2018 expert consensus guidelines on antidote stocking note that while activated charcoal is widely available in hospitals, it was not included in their antidote recommendations specifically because it acts by reducing absorption rather than as a true antidote 2.
Specific Dosing by Age:
- 0-10 years: 10-25 g (1-3 heaping tablespoons) mixed in minimum 8 oz liquid 1
- 10-12 years: 25-50 g (3-6 tablespoons) mixed in minimum 8 oz liquid 1
- >12 years: 25-100 g (3-12 tablespoons) mixed in minimum 8 oz liquid 1
Critical Contraindications (Absolute):
- Unconscious or semi-conscious patients 1
- Patients having convulsions 1
- Impaired airway protective reflexes 3
- Intestinal obstruction 4
Substances NOT Bound by Activated Charcoal:
Do not administer for ingestion of: iron, lithium, alcohols, ethylene glycol, alkalis, fluoride, mineral acids, potassium, turpentine, corrosives (lye), strong acids, or petroleum distillates (kerosene, gasoline, paint thinner, cleaning fluid, furniture polish) 3, 1.
Multiple-Dose Activated Charcoal (MDAC)
MDAC should be considered only for life-threatening ingestions of carbamazepine, dapsone, phenobarbital, quinine, or theophylline 4. These are the only drugs with sufficient evidence demonstrating enhanced elimination, though notably no controlled studies have proven clinical benefit in terms of reduced morbidity or mortality. MDAC reduces drug half-life by approximately 46% and area under the curve by 47% for intravenously administered drugs 5.
Important Clinical Reality:
A critical pitfall exists in current practice: only 16% of overdose patients present within the recommended 1-hour window, yet 97.6% of patients arriving after 60 minutes still receive activated charcoal (mean time 225 minutes post-ingestion) 6. This represents widespread deviation from evidence-based guidelines. The evidence supporting activated charcoal administration beyond 1 hour is limited, and routine use in this timeframe should be avoided unless consulting with a poison control center (1-800-222-1222) 3, 1.
Cathartic Caution:
Do not use sorbitol-containing activated charcoal products in children <1 year old or for repeated doses 3. Fatal hypernatremic dehydration has been reported with repeated sorbitol administration. Non-sorbitol-containing products should be used in these situations.
Simethicone
Simethicone is indicated as an adjunct to improve mucosal visibility during gastrointestinal endoscopy (colonoscopy and esophagogastroduodenoscopy) and to reduce abdominal bloating during bowel preparation 7, 8, 9.
Primary Indications:
1. Colonoscopy Preparation
Simethicone improves colon cleanliness when added to polyethylene glycol (PEG) bowel preparation (OR 1.48) and significantly reduces abdominal bloating (OR 2.33 for bloating with PEG alone vs. PEG + simethicone) 7.
Key nuance: The benefit is most pronounced with single-dose PEG regimens (OR 1.83 for cleanliness; OR 1.96 for adenoma detection rate), but not statistically significant with split-dose regimens 7. This means simethicone should be prioritized for patients unable to receive split-dose PEG preparations.
2. Esophagogastroduodenoscopy (EGD) Preparation
Simethicone solution should be administered 31-60 minutes before EGD for optimal gastric cleanness 8. This timing window achieved 79.3% of patients with Grade A gastric cleanness, compared to only 34.5% when given 20-30 minutes before 8.
For early endoscopy (10-20 minutes), simethicone alone provides similar mucosal visibility to combination therapy (simethicone + N-acetyl cysteine), making it an effective single-agent option when timing is constrained 9.
Mechanism and Effects:
Simethicone is an anti-foaming agent that reduces excessive foam and bubbles in the gastrointestinal tract. It does not reduce nausea, vomiting, or abdominal pain—only bloating and foam 7.
Clinical Algorithm for Simethicone Use:
For colonoscopy preparation:
- If patient requires single-dose PEG → Add simethicone (improves cleanliness and adenoma detection)
- If patient receives split-dose PEG → Simethicone optional (no proven benefit)
For EGD: